A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma

To be considered for this study, you would need to have a confirmed diagnosis of multiple myeloma, and your disease must be measurable, meaning we can track its presence in your blood or urine. You should have already received between one and three previous lines of treatment for your myeloma, including a medicine called a proteasome inhibitor and lenalidomide. If you've only had one previous treatment, it must be clear that your myeloma didn't respond or got worse while on lenalidomide, or within 60 days of stopping it. Your disease must also show signs of progression after your last treatment.

There are also some general health requirements, including having a good enough physical condition to participate in the study, as determined by a standard rating system (ECOG performance status of 0, 1, or 2). Your blood test results and other health checks would need to fall within specific healthy ranges to ensure your safety throughout the trial.

However, some conditions would prevent you from joining. For example, if you have any severe allergies or reactions to any of the study medications, you wouldn't be able to participate. Also, if your myeloma has already been shown to be resistant to pomalidomide, you wouldn't be able to receive the DPd treatment arm meant for comparison. Similar restrictions apply if you are unable to receive the DVd treatment arm.

If you join this study, you will be assigned to receive either the new combination treatment (Tec-Dara) or one of the standard comparison treatments (DPd or DVd). This is done randomly, like flipping a coin, so neither you nor your doctor can choose which treatment you get. You will receive your treatment through injections under the skin (subcutaneously) and possibly other ways, depending on the specific medicines and your assigned group. You'll have regular hospital visits for check-ups, blood tests, and other assessments to monitor your health and how the treatment is working. The total duration of your participation will depend on various factors, including how well you respond to treatment and your overall health, and will involve ongoing follow-up visits.